The changing landscape of treatment options in childhood acute lymphoblastic leukaemia.

Autor: Micallef B; Malta Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN 3000, Malta., Nisticò R; School of Pharmacy, Department of Biology, University of Tor Vergata, Rome, Italy., Sarac SB; Danish Medicines Agency, Copenhagen, Denmark., Bjerrum OW; Danish Medicines Agency, Copenhagen, Denmark; Department of Hematology, Odense University Hospital, Odense, Denmark., Butler D; Malta Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN 3000, Malta., Sammut Bartolo N; Department of Pharmacy, University of Malta, Msida, Malta., Serracino-Inglott A; Malta Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN 3000, Malta; Department of Pharmacy, University of Malta, Msida, Malta., Borg JJ; Malta Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN 3000, Malta; School of Pharmacy, Department of Biology, University of Tor Vergata, Rome, Italy. Electronic address: john-joseph.borg@gov.mt.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2022 May; Vol. 27 (5), pp. 1483-1494. Date of Electronic Publication: 2022 Jan 07.
DOI: 10.1016/j.drudis.2022.01.002
Abstrakt: New paediatric acute lymphoblastic leukaemia (ALL) treatments have been developed and innovative products are in the pipeline. However, despite many active clinical trials, bridging bench science to clinical development to authorised medicines remains challenging. Research in first-line treatment continues to focus on multidrug chemotherapy with the potential addition of new targeted molecules being studied. Research in second- and third-line treatment represents a shift from cytotoxic intensification to an area of precision medicine through emergent innovative and immuno-oncology products. The collaborative research model in ALL involving different stakeholders should intensify to facilitate bench-to-bedside clinical translation for the benefit of patients.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: